PubMed COVID-19 Clinical Care

The viral spike (S) protein on the surface of SARS-CoV-2 binds to angiotensin- converting enzyme 2 (ACE2) receptors on the host cells, facilitating its entry and infection. Here, we designed and prepared functionalized nanofibers targeting the S

CONCLUSIONS: It has been challenging to reach any definitive conclusions regarding the effects of C19V on IARI, conducting extensive, substantial population-based studies that integrate clinical and virological data from more than one season is

CONCLUSIONS: Advanced age and comorbidities such as chronic renal failure and hematologic malignancy in COVID-19 patients are associated with poor survival prognosis in critically ill COVID-19 patients.

This research letter introduces readers to health intelligence by conceptualizing critical components and providing a primer for research within political science broadly considered. Accordingly, a brief review of the literature is provided

OBJECTIVE: During the coronavirus disease (COVID-19) pandemic, face mask wearing was mandated in Port Moresby, Papua New Guinea in July 2020, but compliance was observed to be low. We aimed to determine the frequency of face mask wearing by the

SARS-CoV-2 infection is mainly detected by multiplex real-time RT-PCR from upper respiratory specimens, which is considered the gold-standard technique for SARS-CoV-2 infection diagnosis. A nasopharyngeal (NP) swab represents the clinical sample of

CONCLUSION: Findings from our study support existing research showing the negative impact of COVID-19 on maternal and child health services utilization in sub-Saharan Africa. This study offers subnational and granular estimates of service loss that

CONCLUSIONS: Infusion of umbilical cord-derived MSCs is an effective strategy for treating patients with COVID-19 pneumonia, with no noticeable adverse effects.

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the biggest healthcare issue worldwide. This study aimed to develop a monoclonal antibody against SARS-CoV-2 from B cells of recovered COVID-19 patients, which

CONCLUSIONS AND RELEVANCE: In this multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of the efficacy and safety of FINLAY-FR-2 and FINLAY-FR-1A, 2 doses of FINLAY-FR-2 plus the third dose of FINLAY-FR-1A showed acceptable